Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

Inclusion Criteria: * Acceptable health history to allow blood product collection * Weight \>50\<125 Kg (kilogram). * Male or non-pregnant, non-nursing female. * General good health, as determined by questionnaire. * Normal prescreening complete blood count. * Platelet count\>150 x 10\^3/uL (microliter) at initial screening and \>120 x 10\^3/uL immediately prior to leukapheresis. * Adequate peripheral venous access to allow collection of product. * Able to read, understand, and sign the informed consent form. Additional Inclusion Criteria for Mobilized Subjects * If male, be willing to use a condom during sexual relations with a female partner until 48 hours following the last G-CSF injection. * If female and of childbearing potential, be willing to use a medically acceptable contraceptive until 48 hours following the last G-CSF injection. Exclusion Criteria: * a) Collection or loss of: * more than a ½ pint (1 cup) of whole blood within the prior 56 days or, * more than 3 L (liter) of whole blood or 1.5 L of red blood cells within the prior 12 months or, * more than 12 L of plasma within the prior 12 months or, * a leukapheresis within the prior six weeks or, * a plateletpheresis within the prior 48 hours or two within the prior 7 days or twenty-four within the last 12 months or, * a plasmapheresis within the prior 48 hours or two within the prior 7 days. * Acute or symptomatic chronic lung disease. * Active or chronic heart disease, including hypertension controlled by medication. * History of hematologic malignancy or chronic hematologic disorder or bleeding disorder. * Reactive test indicative of infection with T. pallidum, Human T-lymphotropic virus, HIV, Hepatitis C Virus, or Hepatitis B Virus (except isolated Hepatitis B Core Antibody Reactivity. * Presence of psychological traits or physiological or medical conditions that would make subject unlikely to tolerate the procedures. * Subjects taking prescription medications other than those deemed allowable by the investigator. * Abnormal serum electrolytes or serum calcium levels. * Abnormal serum creatinine level. * Abnormal liver function results on ALT (alanine amino transferase) test. * Abnormal coagulation testing on prothrombin time or partial thromboplastin time. * Inadequate antecubital veins for leukapheresis or inability or unwillingness to tolerate leukapheresis. * If female, pregnant or lactating. Additional Exclusion Criteria for Mobilized Subjects * Received a G-CSF injection in the prior 4 months, or received more than twenty-five (25) doses of G-CSF (a dose includes several individual injections administered on one occasion). * Known hypersensitivity to G-CSF or any E. coli-derived products. * History of autoimmune condition or disorder, unless approved by principal investigator. * Immediate family history (parents, grandparents, siblings, children) of hematologic malignancy. * Active or history of iritis (anterior uveitis) or episcleritis. * History of deep vein thrombosis or pulmonary embolism. * Current treatment with lithium. * Spleen tip palpable during physical exam. * Positive SickleDex test.